Stockscreener 앱 받기
2.23
0.90%
0.02
시간 외 거래:
2.24
0.01
+0.45%
전일 마감가:
$2.21
열려 있는:
$2.22
하루 거래량:
1.33M
Relative Volume:
1.12
시가총액:
$179.34M
수익:
$52.74M
순이익/손실:
$-6.60M
주가수익비율:
-26.39
EPS:
-0.0845
순현금흐름:
$-13.63M
1주 성능:
-20.07%
1개월 성능:
-29.21%
6개월 성능:
+17.99%
1년 성능:
-0.89%
1일 변동 폭
$2.12
$2.25
1주일 범위
$2.0701
$2.92
52주 변동 폭
$1.32
$3.19
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
명칭
Protalix BioTherapeutics Inc.
전화
972 4 988 9488
주소
2 Snunit Street, Science Park PO Box 455, Karmiel
Compare PLX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
2.23 | 177.73M | 52.74M | -6.60M | -13.63M | -0.0845 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-08 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-17 | 재확인 | Rodman & Renshaw | Buy |
| 2016-04-04 | 개시 | Rodman & Renshaw | Buy |
| 2015-04-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2014-11-12 | 재확인 | R. F. Lafferty | Buy |
| 2014-01-24 | 개시 | R. F. Lafferty | Buy |
| 2012-05-02 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | 재확인 | Oppenheimer | Outperform |
| 2012-04-30 | 다운그레이드 | Auriga | Buy → Hold |
| 2011-10-13 | 개시 | Morgan Joseph | Hold |
| 2011-03-17 | 다운그레이드 | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | 재확인 | Oppenheimer | Outperform |
| 2010-10-14 | 재확인 | UBS | Buy |
| 2009-12-02 | 재확인 | Hapoalim | Outperform |
| 2009-09-22 | 개시 | Canaccord Adams | Buy |
| 2009-09-02 | 개시 | Hapoalim | Outperform |
| 2008-12-01 | 재확인 | Oppenheimer | Outperform |
| 2008-03-11 | 개시 | UBS | Buy |
| 2007-11-20 | 개시 | CIBC Wrld Mkts | Sector Outperform |
모두보기
Protalix BioTherapeutics Inc. 주식(PLX)의 최신 뉴스
PLX: HC Wainwright & Co. Reiterates Buy Rating with $12 Target | - GuruFocus
Protalix BioTherapeutics (NYSE:PLX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Protalix targets $78M–$83M 2026 revenue with EU milestone, advancing PRX-115 - MSN
Protalix BioTherapeutics (PLX) TTM Loss Challenges Bullish Profitability Narratives After FY 2025 Results - simplywall.st
Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlig - GuruFocus
PLX: 2025 Full Year Results - Yahoo Finance
Protalix BioTherapeutics (PLX) Misses Earnings Estimates, Projec - GuruFocus
Protalix: Overview of Fourth Quarter Financial Results - Bitget
Protalix (PLX) 2025 10-K details Elfabrio expansion and PRX-115 gout program - Stock Titan
Protalix BioTherapeutics 2025 Annual Report: Innovative Plant Cell-Based Therapeutics, Pipeline, Intellectual Property, and Regulatory Overview - Minichart
Earnings call transcript: Protalix misses EPS, beats revenue in Q4 2025 By Investing.com - Investing.com South Africa
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
PLX: EU approval of Elfabrio's four-week dosing drives revenue growth and strengthens cash position - TradingView
Earnings call transcript: Protalix misses EPS, beats revenue in Q4 2025 - Investing.com
Recap Report: Can Protalix BioTherapeutics Inc keep up with sector leaders2026 Technical Overview & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Protalix BioTherapeutics Financial Results: Quarterly & Annual ReportNews and Statistics - IndexBox
Protalix BioTherapeutics 2025 10-K: $52.7M Revenue, $(6.6)M Net Loss - TradingView
PLX: 2025 revenue reached $52.7M with a net loss of $6.6M as R&D spending increased sharply - TradingView
PLX: 2025 net loss of $6.6M on $52.7M revenue; 2026 revenue outlook $78–83M with pipeline progress - TradingView
Protalix: Q4 Earnings Snapshot - whas11.com
Protalix reports FY2025 results: $52.7M revenue, $6.6M net loss, Q2 2026 EU dosing approval - TradingView
Protalix (PLX) swings to 2025 net loss as R&D spend climbs and assets grow - Stock Titan
Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results - PR Newswire
Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 - Proactive financial news
Earnings Preview: PLX to Report Financial Results Pre-market on March 18 - 富途牛牛
Can Protalix BioTherapeutics Inc sustain its profitabilityMarket Trend Summary & AI Driven Price Forecasts - baoquankhu1.vn
Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026 - Finviz
Rare-disease drug maker Protalix sets 2025 financial results call for March 18 - Stock Titan
Small cap wrap: Medicus Pharma, C3 Metals, Protalix BioTherapeutics… - Proactive Investors
European Commission Approves Once-Every-Four-Weeks Elfabrio® (Pegunigalsidase Alfa) Dosing for Fabry Disease, Reducing Treatment Burden for Adults - Minichart
EC approves new Elfabrio dosing regimen - The Pharma Letter
Protalix BioTherapeutics and partner secure EU approval for new Fabry disease dosing regimen - Proactive financial news
Protalix Biotherapeutics Experiences Valuation Adjustment Amid Strong Market Performance Indicators - Markets Mojo
Chiesi Global Rare Diseases and Protalix BioTherapeutics - GlobeNewswire
Protalix Gains EU Approval for Extended Elfabrio Dosing - TipRanks
Protalix: European Commission approves 2 mg/kg every-4-weeks dosing for Elfabrio - TradingView
EU approves new Elfabrio dosing; Protalix (NYSE: PLX) earns $25M - Stock Titan
EU approves four-week dosing option for Chiesi and Protalix's Elfabrio - marketscreener.com
European Commission Approves New Dosing for Protalix (PLX) Elfab - GuruFocus
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Approval of Additional Dosing Regimen of Every Four Weeks for Elfabrio® (pegunigalsidase alfa) - The Manila Times
Buybacks Report: Is Protalix BioTherapeutics Inc being accumulated by smart money2025 Year in Review & Smart Investment Allocation Insights - baoquankhu1.vn
Why hedge funds are buying Protalix BioTherapeutics Inc. stockWeekly Investment Report & Momentum Based Trading Signals - Naître et grandir
Buybacks Report: Will Protalix BioTherapeutics Inc benefit from government policyJuly 2025 Big Picture & Short-Term High Return Strategies - baoquankhu1.vn
Retail Trends: Should I invest in Protalix BioTherapeutics Inc before earningsJuly 2025 Selloffs & Reliable Volume Spike Alerts - baoquankhu1.vn
MAK Capital Group (PLX) reports 4,649,599 shares, a 5.8% stake - Stock Titan
Published on: 2026-03-01 19:16:31 - baoquankhu1.vn
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Protalix BioTherapeutics Reports First Quarter 2025 Financial an - GuruFocus
PLX Should I Buy - Intellectia AI
Protalix BioTherapeutics (NYSE:PLX) Shares Down 0.7%Time to Sell? - MarketBeat
Protalix Biotherapeutics Hits New 52-Week High of $3.19 - Markets Mojo
Protalix BioTherapeutics Inc. (PLX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):